Bedrijfsoverzicht
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to the development of product candidates specifically designed for cancer treatment. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which entails high research and development costs and a reliance on regulatory approvals for commercialization. This entity employs a workforce of 298 individuals and currently maintains a market capitalization of $1.60B with annual revenue of $62.90M. These valuation and revenue figures indicate that the company holds a significant market capitalization relative to its current revenue stream, reflecting the market's anticipation of future commercial potential from its lead asset, IBTROZI, rather than immediate profitability.
Financiële gezondheid
The company reported a revenue of $62.90M over the trailing twelve months, yet this generated a net income of $-204,627,008 and an EBITDA of $-211,324,992. The substantial disparity between the revenue of $62.90M and the net loss of $-204,627,008 reveals a cost structure where operating expenses, particularly research and development expenditures, significantly exceed current sales revenue. Free cash flow stands at $-115,776,248, indicating that the company is burning cash rapidly, which limits its financial flexibility and necessitates a continued reliance on external capital sources to fund operations. The gross margin is reported at 85.2%, suggesting high efficiency in production costs relative to sales, whereas the operating margin of -81.3% and profit margin of 0.0% highlight severe operational losses and an inability to generate profit from sales at this stage. The company holds $529.21M in cash against $66.94M in debt, resulting in a debt-to-equity ratio of 21.90, which presents a leveraged balance sheet despite the high absolute cash position due to the negative equity implied by losses. A current ratio of 6.95 indicates strong short-term liquidity, as the company possesses nearly seven times the assets required to cover its short-term liabilities. Furthermore, the return on equity is -53.2% and the return on assets is -23.5%, metrics that reveal management is currently utilizing the company's equity and asset base to generate losses rather than returns.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is -31.72, implying that the market expects earnings to remain negative or improve slowly in the near term. The price-to-book ratio stands at 5.22, indicating that the market values the company at a significant premium over its tangible book value, a common characteristic for clinical-stage biotechs with valuable intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 25.42 and the EV/EBITDA of -5.38 suggest that investors are pricing the stock based on pipeline potential rather than current earnings power or sales multiples. The 52-week trading range spans from a low of $1.57 to a high of $9.75, and the current price sits at a level that reflects significant volatility within this established range. With a beta of 1.61, the stock exhibits price volatility that is substantially higher than the broader market, meaning it will likely experience more extreme price swings than the general index.
Growth & Income
Revenue growth year-over-year is reported at an exceptional 633.1%, while earnings growth is N/A due to the company's current lack of profitability. Since earnings are negative, they cannot grow faster than revenue in a traditional sense, but the massive revenue increase suggests a rapid scaling of sales or contract activity relative to the base period. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as the 0.0% payout ratio reflects the reinvestment of all available resources into growth initiatives rather than shareholder distributions. The overall growth and income profile is characterized by explosive revenue expansion paired with a complete absence of current income generation or dividend distributions.